Impact of scheduled partial exchange transfusions on outcomes in pregnant patients with severe sickle cell disease: a retrospective study.

Outcome Pregnancy Red cell exchange SCD Sickle cell disease Transfusion

Journal

Hematology, transfusion and cell therapy
ISSN: 2531-1387
Titre abrégé: Hematol Transfus Cell Ther
Pays: Brazil
ID NLM: 101725732

Informations de publication

Date de publication:
07 Sep 2024
Historique:
received: 09 04 2023
revised: 08 06 2024
accepted: 04 07 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 25 9 2024
Statut: aheadofprint

Résumé

The incidence of feto-maternal complications is high in women with sickle cell disease. The paucity of high-quality evidence has led to conditional recommendations for transfusional support in pregnant patients. This study aimed to assess if scheduled partial red cell exchanges impact pregnancy outcomes in sickle cell disease patients. Forty-seven pregnancies were divided into two groups based on whether patients received scheduled partial red cell exchanges. Collected data included demographics, laboratory values, number of hospital visits, and prenatal/perinatal/postnatal outcomes. Data were analyzed using descriptive statistics, t-test, Chi-square and Fisher's exact tests, and binary regression. The mean age was 25.09 ± 4.39 years. Of 47 patients, 14 (29.8%) received scheduled red cell exchanges with 78.6% compliance with no evidence of alloimmunization. This procedure during pregnancy was associated with fewer admissions for pain crises (p=0.032), higher gestational age at delivery (p=0.007), and a lower incidence of neonatal intensive care admissions (p=0.011; odds ratio: 0.071; 95% confidence interval: 0.008-0.632). Logistic regression did not show any significant associations. Sickle cell disease patients with complications in previous pregnancies, including high hospitalization/admission rates and preterm deliveries, could benefit from scheduled partial red cell exchanges or simple transfusions. Further research is needed to guide clinical practice pertaining to transfusional support in pregnant patients with sickle cell disease.

Identifiants

pubmed: 39322530
pii: S2531-1379(24)00304-3
doi: 10.1016/j.htct.2024.07.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright © 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest None declared.

Auteurs

Anil Ananthaneni (A)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA. Electronic address: anil_kumarans@yahoo.co.in.

Sarah Jones (S)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.

Mohamed Ghoweba (M)

Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

Vishwa Grant (V)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.

Kenna Leethy (K)

Phoenix Children's Hospital, Phoenix, AZ, USA.

Taras Benzar (T)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.

Samip Master (S)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.

Richard Mansour (R)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.

Poornima Ramadas (P)

Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.

Classifications MeSH